Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 7/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13659026 | 0.93 | DGKA (0.55) | DGKALMNANAAALTA4HALDH1A1 | |
| SCHEMBL10351184 | 0.89 | DGKA (0.52) | DGKALMNANAAALTA4HALDH1A1 | |
| SCHEMBL16079775 | 0.87 | DGKA (0.55) | DGKALMNANAAALTA4HALDH1A1 | |
| Diethanolamine SCHEMBL28038154 | 0.86 | DGKA (0.65) | DGKANAAAACHEHTR2CFAAH | |
| SCHEMBL8421899 | 0.86 | DGKA (0.58) | DGKALMNANAAALTA4HALDH1A1 | |
| SCHEMBL11227543 | 0.86 | HTR2C (0.51) | DGKALMNANAAALTA4HALDH1A1 | |
| SCHEMBL11341423 | 0.85 | DGKA (0.52) | DGKALMNANAAALTA4HALDH1A1 | |
| SCHEMBL5417057 | 0.85 | ACHE (0.42) | DGKANAAALTA4HACHEHTR2C | |
| SCHEMBL25340152 | 0.85 | DGKA (0.58) | DGKANAAAACHEHTR2CMGLL | |
| SCHEMBL30448714 | 0.85 | DGKA (0.58) | DGKANAAAACHEHTR2CMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177813-A1 | TREATMENT COMPOSITIONS WITH PRO-FRAGRANCE SILICONE POLYMERS THAT COMPRISE HETEROCYCLIC MOIETIES | THE PROCTER & GAMBLE COMPANY | 2022-06-09 | — | — | US | disclosed |
| US-20210317071-A1 | PH-RESPONSIVE LIPIDS | UNIVERSITY OF KWAZULU-NATAL (ZA) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317071-A1 | PH-RESPONSIVE LIPIDS | FASN, ELOVL1, FFAR1 | DGKA 174/4885LMNA 2052/4885NAAA 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.